Programable Tissue Regeneration

February 2024. [image] Image. Programable Tissue Regeneration.

AIMER target areas of impact: Cardiovascular Health Heart Disease and Heart Attacks: Annual cost of $240 billion 805,000 heart attacks per year, 630,000 being first-time occurrences 695,000 deaths from post-heart attack complications Wound Management Annual cost: $96.8 billion Chronic wounds alone contribute $28 billion to this figure Osteoarthritis & Musculoskeletal Issues Attributable cost: $185 billion Spinal Cord Injuries 18,000 incidents per year Lifetime cost: $2.85 million per person or $54 billion annually Diabetes Complications Annual cost: $37 billion.

2. Total Addressable Market. Addressable With Our AIMER Technology.

Step 1 AIMER NPs Applied To Injury. 3. Introduction: AIMER - Regenerative Nanotherapeutics.

Regenerative Healing Biomaterials Angiogenesis Thermal regulation Drug delivery ECM substitute Stem cells Angiogenesis Immuno-modulation Paracrine-activity ECM-deposition Growth factors Immune/endogenous cell activation Angiogenesis ECM deposition Tissue engineering Angiogenesis Functional tissue substitute.

Wound Healing. Mouse Day 6 1cm2. 5. Key Data Supporting Our Solutions.

Cartilage, ACL Regeneration. Injection of AIMER NPs with cartilage paste.

Initiate and complete FDA work to Phase IIa Partner with a Global Major to commercialize into Healthcare Our First Indications to commercialize: Dermatological Wound Healing Orthopedic Summary of Advantages: Extensive data in Murine and Porcine species (⍺-1,3GT Knockout) Human safety and tolerance end points were met by others for cancer in a successful Phase I/IIa trial Complimentary with existing standards of care.

Richard Strafehl - Co-founder. Seasoned entrepreneur, CEO level, business development, 15 years and 3 startups in life sciences. Previously in fintech, SAS, real estate and information technology..

Jason A. Spector, M.D., FACS. Chief of the Division of Plastic and Reconstructive Surgery - Weill Cornell Medicine in New York City. Dr. Spector is the Director and Principal Investigator of the Laboratory for Bioregenerative Medicine and Surgery. He worked with Dr. Galili on Wound Healing. He is an advisor to us for skin wound healing applications..

$3M. 2024- Non-GMP Manufacture Toxicity & Safety Studies.

Proof of concept in animal species: Dermatological wounds Cardiac Orthopedic Axonal nerve regeneration Proof of Concepts in Human demonstrate efficacy, tolerance: ACL tendon Cancer CRO selected for Safety and Toxicity Orthopedic collaboration partner established.

Strong, commercially-minded management team Experienced team with a clear focus on completing Phase IIa and establishing a global partner to commercialize. Innovative Solution that will change the standard of care AIMER's broad applicability across wounds, surgeries, and various treatment methods holds the promise to revolutionize existing treatment standards. Patent protected – 4 issued US Patents for all indications presented, and more. Streamlined FDA approval process Low regulatory risk based on known safety/toxicity, short time, well defined clinical endpoints. Coupled with a high likelihood of reimbursement due to cost-effective production and significant medical ROI. Large and growing addressable market Tapping into a $250B+ market, accelerated by global healthcare trends, from aging to the rise in chronic conditions..